Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 19/20 | 0.69 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9910504 | 0.75 | MET (0.77) | MET | |
| SCHEMBL2698089 | 0.71 | MET (0.71) | MET | |
| SCHEMBL18885783 | 0.71 | MET (0.79) | MET | |
| SCHEMBL20457277 | 0.70 | MET (0.56) | METFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL2700939 | 0.69 | MET (1.00) | MET | |
| SCHEMBL9910391 | 0.68 | MET (0.59) | MET | |
| SCHEMBL12049244 | 0.67 | MET (0.65) | MET | |
| SCHEMBL3592241 | 0.67 | MET (0.61) | MET | |
| SCHEMBL18885867 | 0.67 | MET (1.00) | MET | |
| SCHEMBL9910467 | 0.67 | MET (1.00) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524900-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | MET 3/4885FGFR1 10/4885FGFR2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.